董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John C. Chapman | 男 | Director | 68 | 29.00万美元 | 未持股 | 2022-11-29 |
| Timothy C. Crew | 男 | Chief Executive Officer, Director | 61 | 353.24万美元 | 未持股 | 2022-11-29 |
| Melissa Rewolinski | 女 | Director | 53 | 29.00万美元 | 未持股 | 2022-11-29 |
| Jeffrey Farber | 男 | Director | 62 | 29.00万美元 | 未持股 | 2022-11-29 |
| David Drabik | 男 | Director | 54 | 31.40万美元 | 未持股 | 2022-11-29 |
| Patrick G. LePore | 男 | Chairman of the Board | 67 | 32.00万美元 | 未持股 | 2022-11-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John M. Abt | 男 | Vice President and Chief Quality, IT and Operations Officer | 57 | 100.46万美元 | 未持股 | 2022-11-29 |
| Samuel H. Israel | 男 | General Counsel and Chief Legal Officer | 60 | 122.19万美元 | 未持股 | 2022-11-29 |
| John Kozlowski | 男 | Vice President of Finance, Chief Financial Officer and Principal Accounting Officer | 50 | 120.96万美元 | 未持股 | 2022-11-29 |
| Timothy C. Crew | 男 | Chief Executive Officer, Director | 61 | 353.24万美元 | 未持股 | 2022-11-29 |
| Maureen M. Cavanaugh | 女 | Senior Vice President and Chief Commercial Operations Officer | 63 | 129.09万美元 | 未持股 | 2022-11-29 |
董事简历
中英对照 | 中文 | 英文- John C. Chapman
-
JohnC.Chapman于2018年7月被任命为公司董事。Chapman先生是毕马威会计师事务所（KPMG）的退休审计合伙人，专门为大型复杂的跨国制药和消费市场公司提供审计服务。任职KPMG公司期间，他曾担任公司的董事会成员6年，也曾担任KPMG公司的全球制药和化学品主席数年。Chapman先生还担任毕马威会计师事务所（KPMG&8217；）的一些最大客户的全球首席合伙人，其中包括辉瑞（Pfizer），赫斯特（Hoechst）和百事可乐（PepsiCo）等。Chapman先生是一名注册会计师，在纽约佩斯大学（Pace University，New York）获得会计实务工商管理学士学位。
John C. Chapman was appointed as a Director of the Company in July 2018. Mr. Chapman is a retired audit partner for KPMG, having specialized in providing audit services to large complex multinational pharmaceutical and consumer market companies. During his tenure at KPMG, he served for six years as a member of the firm's board of directors and for several years as KPMG's global chair of pharmaceuticals and chemicals. Mr. Chapman also served as global lead partner for some of KPMG's largest clients, including Pfizer, Hoechst and PepsiCo, among others. Mr. Chapman, a certified public accountant, earned a Bachelor of Business Administration in accounting practice degree from Pace University, New York. - JohnC.Chapman于2018年7月被任命为公司董事。Chapman先生是毕马威会计师事务所（KPMG）的退休审计合伙人，专门为大型复杂的跨国制药和消费市场公司提供审计服务。任职KPMG公司期间，他曾担任公司的董事会成员6年，也曾担任KPMG公司的全球制药和化学品主席数年。Chapman先生还担任毕马威会计师事务所（KPMG&8217；）的一些最大客户的全球首席合伙人，其中包括辉瑞（Pfizer），赫斯特（Hoechst）和百事可乐（PepsiCo）等。Chapman先生是一名注册会计师，在纽约佩斯大学（Pace University，New York）获得会计实务工商管理学士学位。
- John C. Chapman was appointed as a Director of the Company in July 2018. Mr. Chapman is a retired audit partner for KPMG, having specialized in providing audit services to large complex multinational pharmaceutical and consumer market companies. During his tenure at KPMG, he served for six years as a member of the firm's board of directors and for several years as KPMG's global chair of pharmaceuticals and chemicals. Mr. Chapman also served as global lead partner for some of KPMG's largest clients, including Pfizer, Hoechst and PepsiCo, among others. Mr. Chapman, a certified public accountant, earned a Bachelor of Business Administration in accounting practice degree from Pace University, New York.
- Timothy C. Crew
-
TimothyC.Crew于2018年1月被任命为公司首席执行官兼董事。Crew先生在仿制药和品牌制药行业拥有超过30年的经验。此前，他曾担任Cipla North America公司（全球制药公司，位于印度孟买）的首席执行官。任职Cipla公司之前，他曾任职Teva Pharmaceuticals Industries Ltd.8年，在那里他最终担任北美仿制药部门的高级副总裁和商业运营官，该部门是全球最大的仿制药公司，年销售额达数十亿美元。在此之前，他是Teva&；8217；的Vice President、联盟和业务开发人员。Crew先生还是雷迪博士实验室有限公司（Dr.Reddy’；s Laboratories Ltd.）北美Vice President的一名高管。Crew先生在百时美施贵宝（Bristol-Myers Squibb）开始了他的制药职业生涯，他在该公司担任过多个全球营销、管理梦百合、营销、业务发展和战略规划方面的高级管理职位。在担任制药职务之前，Crew先生曾在美国陆军（United States Army）服役，在那里他晋升为上尉。Crew先生在波莫纳学院（Pomona College）获得经济学文学学士学位，并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
Timothy C. Crew was appointed as the Company's Chief Executive Officer and a Director of the Company in January 2018. Mr. Crew has more than 30 years of experience in the generic and branded pharmaceutical industries. Previously, he served as Chief Executive Officer of Cipla North America, a global pharmaceutical company based in Mumbai, India. Before Cipla, he worked for eight years at Teva Pharmaceuticals Industries Ltd. "Teva", where he ultimately served as Senior Vice President and Commercial Operating Officer of the North American Generics division, the world's largest generic operation with multibillion dollars of annual sales. Before that, he was Teva's Vice President, Alliances and Business Development. Mr. Crew was also an Executive Vice President, North America, for Dr. Reddy's Laboratories Ltd. Mr. Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development and strategic planning. Prior to his pharmaceutical roles, Mr. Crew served in the United States Army, where he rose to the rank of Captain. Mr. Crew earned a Bachelor of Arts degree in economics from Pomona College and a Masters of Business Administration degree from Columbia Business School. - TimothyC.Crew于2018年1月被任命为公司首席执行官兼董事。Crew先生在仿制药和品牌制药行业拥有超过30年的经验。此前，他曾担任Cipla North America公司（全球制药公司，位于印度孟买）的首席执行官。任职Cipla公司之前，他曾任职Teva Pharmaceuticals Industries Ltd.8年，在那里他最终担任北美仿制药部门的高级副总裁和商业运营官，该部门是全球最大的仿制药公司，年销售额达数十亿美元。在此之前，他是Teva&；8217；的Vice President、联盟和业务开发人员。Crew先生还是雷迪博士实验室有限公司（Dr.Reddy’；s Laboratories Ltd.）北美Vice President的一名高管。Crew先生在百时美施贵宝（Bristol-Myers Squibb）开始了他的制药职业生涯，他在该公司担任过多个全球营销、管理梦百合、营销、业务发展和战略规划方面的高级管理职位。在担任制药职务之前，Crew先生曾在美国陆军（United States Army）服役，在那里他晋升为上尉。Crew先生在波莫纳学院（Pomona College）获得经济学文学学士学位，并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
- Timothy C. Crew was appointed as the Company's Chief Executive Officer and a Director of the Company in January 2018. Mr. Crew has more than 30 years of experience in the generic and branded pharmaceutical industries. Previously, he served as Chief Executive Officer of Cipla North America, a global pharmaceutical company based in Mumbai, India. Before Cipla, he worked for eight years at Teva Pharmaceuticals Industries Ltd. "Teva", where he ultimately served as Senior Vice President and Commercial Operating Officer of the North American Generics division, the world's largest generic operation with multibillion dollars of annual sales. Before that, he was Teva's Vice President, Alliances and Business Development. Mr. Crew was also an Executive Vice President, North America, for Dr. Reddy's Laboratories Ltd. Mr. Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development and strategic planning. Prior to his pharmaceutical roles, Mr. Crew served in the United States Army, where he rose to the rank of Captain. Mr. Crew earned a Bachelor of Arts degree in economics from Pomona College and a Masters of Business Administration degree from Columbia Business School.
- Melissa Rewolinski
-
Melissa Rewolinski于2019年7月被任命为公司董事。Rewolinski博士目前担任MVR Consulting的负责人，在那里她专门为中小型生物技术和制药公司提供法律顾问。早些时候，她曾担任Intercept公司的多个高级研发职位，并升任高级副总裁，技术运营主管和执行团队成员。此前，她曾担任Amira Pharmaceuticals公司的高级开发董事，此前曾担任Pfizer Global R&D公司的化学开发集团领导人和药物科学项目团队负责人。Rewolinski博士在Pharmacia&Upjohn开始她的职业生涯，担任博士后研究科学家。Rewolinski博士在莱斯大学（Rice University）以优异成绩获得有机化学博士学位和化学理学学士学位。
Melissa Rewolinski was appointed as a Director of the Company in July 2019. Dr. Rewolinski is a National Association of Corporate Governance Fellow. Dr. Rewolinski currently serves as principal of MVR Consulting, where she specializes in providing counsel to small and mid-size biotechnology and pharmaceutical companies. Earlier she held a number of senior level R&D positions for Intercept, rising to Senior Vice President, Head of Technical Operations, and member of the Executive Team. Previously, she served as Senior Director, Development for Amira Pharmaceuticals, and before that as a Chemical Development Group Leader and a Pharmaceutical Sciences Project Team Leader for Pfizer Global R&D. Dr. Rewolinski began her career at Pharmacia & Upjohn as a post-doctoral research scientist. She is a member of the Board of Directors of ATCC American Type Culture Collection, a private, nonprofit, global biological resource center and standards organization that provides scientists with the biomaterials and resources they need to conduct critical life science research. Dr. Rewolinski earned a Doctorate degree in Organic Chemistry and Bachelor of Science degree in Chemistry, magna cum laude, from Rice University. - Melissa Rewolinski于2019年7月被任命为公司董事。Rewolinski博士目前担任MVR Consulting的负责人，在那里她专门为中小型生物技术和制药公司提供法律顾问。早些时候，她曾担任Intercept公司的多个高级研发职位，并升任高级副总裁，技术运营主管和执行团队成员。此前，她曾担任Amira Pharmaceuticals公司的高级开发董事，此前曾担任Pfizer Global R&D公司的化学开发集团领导人和药物科学项目团队负责人。Rewolinski博士在Pharmacia&Upjohn开始她的职业生涯，担任博士后研究科学家。Rewolinski博士在莱斯大学（Rice University）以优异成绩获得有机化学博士学位和化学理学学士学位。
- Melissa Rewolinski was appointed as a Director of the Company in July 2019. Dr. Rewolinski is a National Association of Corporate Governance Fellow. Dr. Rewolinski currently serves as principal of MVR Consulting, where she specializes in providing counsel to small and mid-size biotechnology and pharmaceutical companies. Earlier she held a number of senior level R&D positions for Intercept, rising to Senior Vice President, Head of Technical Operations, and member of the Executive Team. Previously, she served as Senior Director, Development for Amira Pharmaceuticals, and before that as a Chemical Development Group Leader and a Pharmaceutical Sciences Project Team Leader for Pfizer Global R&D. Dr. Rewolinski began her career at Pharmacia & Upjohn as a post-doctoral research scientist. She is a member of the Board of Directors of ATCC American Type Culture Collection, a private, nonprofit, global biological resource center and standards organization that provides scientists with the biomaterials and resources they need to conduct critical life science research. Dr. Rewolinski earned a Doctorate degree in Organic Chemistry and Bachelor of Science degree in Chemistry, magna cum laude, from Rice University.
- Jeffrey Farber
-
Jeffrey Farber，于2006年5月被选为该公司的一位董事，于2012年7月被任命为董事长。他是于2003年8月加入该公司并担任秘书的。自1994年以来，他一直是一家全国性仿制药经销商- Auburn Pharmaceutical“Auburn”的总裁及所有者。在开始经营Auburn之前，他曾在Major Pharmaceutical （“Major”）工作了超过15年，担任过各种职务。在Major的时候，他曾参与销售与采购工作，最终担任中西部的总裁。他还曾在Major的制造部- Vitarine Pharmaceuticals工作过，在那里他曾在该董事会任职。Farber先生是在Western Michigan大学毕业并获得工商管理学士学位的，并且参与了Long Island大学的药房管理研究生项目。他是该公司的董事会荣誉董事长- Jeffrey Farber的儿子。
Jeffrey Farber was appointed a Director of the Company in May 2006 and was appointed Chairman of the Board of Directors in July 2012. In July 2018 Patrick LePore succeeded Jeffrey Farber as the Chairman of the Board. Jeffrey Farber joined the Company in August 2003 as Secretary. Since 1994 Mr. Farber has been President and the owner of Auburn Pharmaceutical "Auburn", a national generic pharmaceutical distributor. Prior to starting Auburn, Mr. Farber served in various positions at Major Pharmaceutical ("Major"), where he was employed for over 15 years. At Major, Mr. Farber was involved in sales, purchasing and eventually served as President of the Midwest division. Mr. Farber also spent time working at Major's manufacturing division, Vitarine Pharmaceuticals, where he served on its Board of Directors. Mr. Farber graduated from Western Michigan University with a Bachelor of Science Degree in Business Administration and participated in the Pharmacy Management Graduate Program at Long Island University. Mr. Farber will not be standing for re-election to the Board for 2023. - Jeffrey Farber，于2006年5月被选为该公司的一位董事，于2012年7月被任命为董事长。他是于2003年8月加入该公司并担任秘书的。自1994年以来，他一直是一家全国性仿制药经销商- Auburn Pharmaceutical“Auburn”的总裁及所有者。在开始经营Auburn之前，他曾在Major Pharmaceutical （“Major”）工作了超过15年，担任过各种职务。在Major的时候，他曾参与销售与采购工作，最终担任中西部的总裁。他还曾在Major的制造部- Vitarine Pharmaceuticals工作过，在那里他曾在该董事会任职。Farber先生是在Western Michigan大学毕业并获得工商管理学士学位的，并且参与了Long Island大学的药房管理研究生项目。他是该公司的董事会荣誉董事长- Jeffrey Farber的儿子。
- Jeffrey Farber was appointed a Director of the Company in May 2006 and was appointed Chairman of the Board of Directors in July 2012. In July 2018 Patrick LePore succeeded Jeffrey Farber as the Chairman of the Board. Jeffrey Farber joined the Company in August 2003 as Secretary. Since 1994 Mr. Farber has been President and the owner of Auburn Pharmaceutical "Auburn", a national generic pharmaceutical distributor. Prior to starting Auburn, Mr. Farber served in various positions at Major Pharmaceutical ("Major"), where he was employed for over 15 years. At Major, Mr. Farber was involved in sales, purchasing and eventually served as President of the Midwest division. Mr. Farber also spent time working at Major's manufacturing division, Vitarine Pharmaceuticals, where he served on its Board of Directors. Mr. Farber graduated from Western Michigan University with a Bachelor of Science Degree in Business Administration and participated in the Pharmacy Management Graduate Program at Long Island University. Mr. Farber will not be standing for re-election to the Board for 2023.
- David Drabik
-
David Drabik，于2011年1月被推选为该公司的董事。他是公司董事会管理国家协会的一位成员。自2002年以来，他一直在一家主要为私募股权和风险投资团体服务的咨询公司- Cranbrook 有限公司"Cranbrook"的总裁。在Cranbrook时，他曾协助和建议该公司的客户源、构建和管理私人股本以及风险投资交易。在1995-2002年期间，他曾在纽约市（New York City）一家管理着15亿美元的私人股本和风险投资公司- UBS Capital Americas（前身为UBS Capital LLC）担任各种职位。在1992-1995年期间，他曾是瑞士联合银行（Union Bank of Switzerland）的纽约市（New York City）企业和机构银行事业部的一位银行家。他是从Michigan大学毕业并获得工商管理学士学位的。
David Drabik was elected a Director of the Company in January 2011. Mr. Drabik is a National Association of Corporate Directors Governance Fellow. Since 2002 Mr. Drabik has been President of Cranbrook & Co., LLC "Cranbrook", an advisory firm primarily serving the private equity and venture capital community. At Cranbrook, Mr. Drabik assists and advises its clientele on originating, structuring and executing private equity and venture capital transactions. From 1995 to 2002 Mr. Drabik served in various roles and positions with UBS Capital Americas (and its predecessor UBS Capital LLC), a New York City based private equity and venture capital firm that managed $1.5 billion of capital. From 1992 to 1995 Mr. Drabik was a banker with Union Bank of Switzerland's Corporate and Institutional Banking division in New York City. Mr. Drabik graduated from the University of Michigan with a Bachelor of Business Administration degree. - David Drabik，于2011年1月被推选为该公司的董事。他是公司董事会管理国家协会的一位成员。自2002年以来，他一直在一家主要为私募股权和风险投资团体服务的咨询公司- Cranbrook 有限公司"Cranbrook"的总裁。在Cranbrook时，他曾协助和建议该公司的客户源、构建和管理私人股本以及风险投资交易。在1995-2002年期间，他曾在纽约市（New York City）一家管理着15亿美元的私人股本和风险投资公司- UBS Capital Americas（前身为UBS Capital LLC）担任各种职位。在1992-1995年期间，他曾是瑞士联合银行（Union Bank of Switzerland）的纽约市（New York City）企业和机构银行事业部的一位银行家。他是从Michigan大学毕业并获得工商管理学士学位的。
- David Drabik was elected a Director of the Company in January 2011. Mr. Drabik is a National Association of Corporate Directors Governance Fellow. Since 2002 Mr. Drabik has been President of Cranbrook & Co., LLC "Cranbrook", an advisory firm primarily serving the private equity and venture capital community. At Cranbrook, Mr. Drabik assists and advises its clientele on originating, structuring and executing private equity and venture capital transactions. From 1995 to 2002 Mr. Drabik served in various roles and positions with UBS Capital Americas (and its predecessor UBS Capital LLC), a New York City based private equity and venture capital firm that managed $1.5 billion of capital. From 1992 to 1995 Mr. Drabik was a banker with Union Bank of Switzerland's Corporate and Institutional Banking division in New York City. Mr. Drabik graduated from the University of Michigan with a Bachelor of Business Administration degree.
- Patrick G. LePore
-
Patrick G. LePore， 于2013年1月14日被任命到该董事会。目前是薪酬委员会的一位成员。2007-2012年期间，在Par Pharmaceutical Companies股份有限公司担任董事长。还曾在该公司担任首席执行官一直到该公司于2012年被私募股权投资公司TPG收购。在加入Par Pharmaceutical Companies股份有限公司之前，他曾是Cardinal Health股份有限公司医疗市场部总裁。他是从Villanova大学获得他的学士学位的，目前是该校的一位受托人；以及是从Fairleigh Dickinson大学获得他的工商管理硕士学位的。
Patrick G. LePore was appointed as a Director of the Company in July 2017. On July 1 2018 Mr. LePore succeeded Mr. Farber as Chairman of the Board of Directors. Mr. LePore served as chairman, Chief Executive Officer and president of PAR Pharmaceuticals, Inc., until the company's acquisition by private equity investor TPG in 2012. He remained as chairman of the new company through the sale of the company to Endo Pharmaceuticals. Mr. LePore began his career with Hoffmann LaRoche. Later, he founded Boron LePore and Associates, a medical communications company, which he took public and was eventually sold to Cardinal Health. Mr. LePore is the Vice Chairman of the board of Matinas BioPharm. On September 10 2020 Mr. LePore was appointed as a director of the board of VYNE Therapeutics, Inc. Mr. LePore earned his bachelor's degree from Villanova University and Master of Business Administration from Fairleigh Dickinson University. - Patrick G. LePore， 于2013年1月14日被任命到该董事会。目前是薪酬委员会的一位成员。2007-2012年期间，在Par Pharmaceutical Companies股份有限公司担任董事长。还曾在该公司担任首席执行官一直到该公司于2012年被私募股权投资公司TPG收购。在加入Par Pharmaceutical Companies股份有限公司之前，他曾是Cardinal Health股份有限公司医疗市场部总裁。他是从Villanova大学获得他的学士学位的，目前是该校的一位受托人；以及是从Fairleigh Dickinson大学获得他的工商管理硕士学位的。
- Patrick G. LePore was appointed as a Director of the Company in July 2017. On July 1 2018 Mr. LePore succeeded Mr. Farber as Chairman of the Board of Directors. Mr. LePore served as chairman, Chief Executive Officer and president of PAR Pharmaceuticals, Inc., until the company's acquisition by private equity investor TPG in 2012. He remained as chairman of the new company through the sale of the company to Endo Pharmaceuticals. Mr. LePore began his career with Hoffmann LaRoche. Later, he founded Boron LePore and Associates, a medical communications company, which he took public and was eventually sold to Cardinal Health. Mr. LePore is the Vice Chairman of the board of Matinas BioPharm. On September 10 2020 Mr. LePore was appointed as a director of the board of VYNE Therapeutics, Inc. Mr. LePore earned his bachelor's degree from Villanova University and Master of Business Administration from Fairleigh Dickinson University.
高管简历
中英对照 | 中文 | 英文- John M. Abt
John M. Abt于2015年3月加入公司担任品质的副总裁。在加入公司之前，他在质量和操作领域担任高层职位，拥有广博的医药制造、网站质量、战略、业务改进和网站转换知识。他最近担任Teva Pharmaceuticals全球质量战略的副总裁，监督全球质量组织战略和相关措施的发展与实施。在此之前，他担任过一系列运营，持续改进，质量系统和遵从性的领导职位，责任增加。他获得John Hopkins University的工商管理硕士学位和Niagara University的生物化学学士学位。
John M. Abt joined the Company in March 2015 as Vice President of Quality and was promoted to Vice President and Chief Quality and Operations Officer in April 2018. In December 2021 Mr. Abt was also appointed Chief IT Officer. Prior to joining the Company, Mr. Abt held senior level positions in both quality and operations and has extensive knowledge in pharmaceutical manufacturing, quality, strategy, business improvement and site transformation. Prior to joining the Company, he most recently served as Teva Pharmaceuticals' Vice President Global Quality Strategy, overseeing the development and implementation of strategy and associated initiatives for the global quality organization. Before that, he held a number of leadership positions of increasing responsibility in operations, continuous improvement, quality systems and compliance. He earned his Doctorate in Business Administration from Temple University, Masters of Administrative Science in Business Management from Johns Hopkins University and a Bachelor of Science in Biochemistry from Niagara University.- John M. Abt于2015年3月加入公司担任品质的副总裁。在加入公司之前，他在质量和操作领域担任高层职位，拥有广博的医药制造、网站质量、战略、业务改进和网站转换知识。他最近担任Teva Pharmaceuticals全球质量战略的副总裁，监督全球质量组织战略和相关措施的发展与实施。在此之前，他担任过一系列运营，持续改进，质量系统和遵从性的领导职位，责任增加。他获得John Hopkins University的工商管理硕士学位和Niagara University的生物化学学士学位。
- John M. Abt joined the Company in March 2015 as Vice President of Quality and was promoted to Vice President and Chief Quality and Operations Officer in April 2018. In December 2021 Mr. Abt was also appointed Chief IT Officer. Prior to joining the Company, Mr. Abt held senior level positions in both quality and operations and has extensive knowledge in pharmaceutical manufacturing, quality, strategy, business improvement and site transformation. Prior to joining the Company, he most recently served as Teva Pharmaceuticals' Vice President Global Quality Strategy, overseeing the development and implementation of strategy and associated initiatives for the global quality organization. Before that, he held a number of leadership positions of increasing responsibility in operations, continuous improvement, quality systems and compliance. He earned his Doctorate in Business Administration from Temple University, Masters of Administrative Science in Business Management from Johns Hopkins University and a Bachelor of Science in Biochemistry from Niagara University.
- Samuel H. Israel
SamuelH.Israel于2017年7月加入公司，担任总法律顾问兼首席法务官。加入Lannett之前，Israel自1998年起担任Fox Rothschild LLP（一家全国性全方位服务律师事务所，拥有26个办事处，在60多个实践领域提供服务）合伙人。他曾担任公司的制药和生物技术实践的主席，并处理多种商业诉讼事务。Israel先生在宾夕法尼亚大学（University of Pennsylvania）获得化学工程理学士学位，并在罗格斯大学法学院（Rutgers University School of Law）以优异成绩获得法学博士学位。
Samuel H. Israel joined the Company in July 2017 as General Counsel and Chief Legal Officer. Prior to joining Lannett, Mr. Israel was a partner with Fox Rothschild LLP, a national, full-service law firm, with 29 offices that provide services in more than 70 practice areas, since 1998. He served as chair of the firm's Pharmaceutical and Biotechnology Practice and handled a variety of commercial litigation matters. Mr. Israel earned a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and a Juris Doctor degree with honors from Rutgers University School of Law.- SamuelH.Israel于2017年7月加入公司，担任总法律顾问兼首席法务官。加入Lannett之前，Israel自1998年起担任Fox Rothschild LLP（一家全国性全方位服务律师事务所，拥有26个办事处，在60多个实践领域提供服务）合伙人。他曾担任公司的制药和生物技术实践的主席，并处理多种商业诉讼事务。Israel先生在宾夕法尼亚大学（University of Pennsylvania）获得化学工程理学士学位，并在罗格斯大学法学院（Rutgers University School of Law）以优异成绩获得法学博士学位。
- Samuel H. Israel joined the Company in July 2017 as General Counsel and Chief Legal Officer. Prior to joining Lannett, Mr. Israel was a partner with Fox Rothschild LLP, a national, full-service law firm, with 29 offices that provide services in more than 70 practice areas, since 1998. He served as chair of the firm's Pharmaceutical and Biotechnology Practice and handled a variety of commercial litigation matters. Mr. Israel earned a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and a Juris Doctor degree with honors from Rutgers University School of Law.
- John Kozlowski
John Kozlowski于2009年加入公司，并于2010年晋升为公司财务总监。2016年，Kozlowski先生晋升为Vice President金融运营和公司财务总监。2017年10月，Kozlowski先生晋升为首席运营官。2018年4月，Kozlowski先生晋升为参谋长兼战略官。2019年8月，科兹洛夫斯基先生接替马丁·加尔万（Martin Galvan）担任金融和首席财务官Vice President。2020年7月，Kozlowski先生还被任命为首席会计官。在加入公司之前，Kozlowski先生曾在Optium Corporation和Finisar Australia担任高级财务和会计职位。他在詹姆斯麦迪逊大学（James Madison University）获得金融学文学学士学位，在莱德大学（Rider University）获得工商管理硕士学位。
John Kozlowski joined the Company in 2009 and was promoted in 2010 to Corporate Controller. In 2016 Mr. Kozlowski was promoted to Vice President Financial Operations & Corporate Controller. In October 2017 Mr. Kozlowski was promoted to Chief Operating Officer. In April 2018 Mr. Kozlowski was promoted to Chief of Staff and Strategy Officer. Mr. Kozlowski was appointed as the Vice President of Finance and Chief Financial Officer in August 2019. In July 2020 Mr. Kozlowski was also appointed the Principal Accounting Officer. Prior to joining the Company, Mr. Kozlowski served in senior finance and accounting roles for Optium Corporation and Finisar Australia. He earned a Bachelor of Arts degree in finance from James Madison University and a Masters of Business Administration degree from Rider University.- John Kozlowski于2009年加入公司，并于2010年晋升为公司财务总监。2016年，Kozlowski先生晋升为Vice President金融运营和公司财务总监。2017年10月，Kozlowski先生晋升为首席运营官。2018年4月，Kozlowski先生晋升为参谋长兼战略官。2019年8月，科兹洛夫斯基先生接替马丁·加尔万（Martin Galvan）担任金融和首席财务官Vice President。2020年7月，Kozlowski先生还被任命为首席会计官。在加入公司之前，Kozlowski先生曾在Optium Corporation和Finisar Australia担任高级财务和会计职位。他在詹姆斯麦迪逊大学（James Madison University）获得金融学文学学士学位，在莱德大学（Rider University）获得工商管理硕士学位。
- John Kozlowski joined the Company in 2009 and was promoted in 2010 to Corporate Controller. In 2016 Mr. Kozlowski was promoted to Vice President Financial Operations & Corporate Controller. In October 2017 Mr. Kozlowski was promoted to Chief Operating Officer. In April 2018 Mr. Kozlowski was promoted to Chief of Staff and Strategy Officer. Mr. Kozlowski was appointed as the Vice President of Finance and Chief Financial Officer in August 2019. In July 2020 Mr. Kozlowski was also appointed the Principal Accounting Officer. Prior to joining the Company, Mr. Kozlowski served in senior finance and accounting roles for Optium Corporation and Finisar Australia. He earned a Bachelor of Arts degree in finance from James Madison University and a Masters of Business Administration degree from Rider University.
- Timothy C. Crew
TimothyC.Crew于2018年1月被任命为公司首席执行官兼董事。Crew先生在仿制药和品牌制药行业拥有超过30年的经验。此前，他曾担任Cipla North America公司（全球制药公司，位于印度孟买）的首席执行官。任职Cipla公司之前，他曾任职Teva Pharmaceuticals Industries Ltd.8年，在那里他最终担任北美仿制药部门的高级副总裁和商业运营官，该部门是全球最大的仿制药公司，年销售额达数十亿美元。在此之前，他是Teva&；8217；的Vice President、联盟和业务开发人员。Crew先生还是雷迪博士实验室有限公司（Dr.Reddy’；s Laboratories Ltd.）北美Vice President的一名高管。Crew先生在百时美施贵宝（Bristol-Myers Squibb）开始了他的制药职业生涯，他在该公司担任过多个全球营销、管理梦百合、营销、业务发展和战略规划方面的高级管理职位。在担任制药职务之前，Crew先生曾在美国陆军（United States Army）服役，在那里他晋升为上尉。Crew先生在波莫纳学院（Pomona College）获得经济学文学学士学位，并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
Timothy C. Crew was appointed as the Company's Chief Executive Officer and a Director of the Company in January 2018. Mr. Crew has more than 30 years of experience in the generic and branded pharmaceutical industries. Previously, he served as Chief Executive Officer of Cipla North America, a global pharmaceutical company based in Mumbai, India. Before Cipla, he worked for eight years at Teva Pharmaceuticals Industries Ltd. "Teva", where he ultimately served as Senior Vice President and Commercial Operating Officer of the North American Generics division, the world's largest generic operation with multibillion dollars of annual sales. Before that, he was Teva's Vice President, Alliances and Business Development. Mr. Crew was also an Executive Vice President, North America, for Dr. Reddy's Laboratories Ltd. Mr. Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development and strategic planning. Prior to his pharmaceutical roles, Mr. Crew served in the United States Army, where he rose to the rank of Captain. Mr. Crew earned a Bachelor of Arts degree in economics from Pomona College and a Masters of Business Administration degree from Columbia Business School.- TimothyC.Crew于2018年1月被任命为公司首席执行官兼董事。Crew先生在仿制药和品牌制药行业拥有超过30年的经验。此前，他曾担任Cipla North America公司（全球制药公司，位于印度孟买）的首席执行官。任职Cipla公司之前，他曾任职Teva Pharmaceuticals Industries Ltd.8年，在那里他最终担任北美仿制药部门的高级副总裁和商业运营官，该部门是全球最大的仿制药公司，年销售额达数十亿美元。在此之前，他是Teva&；8217；的Vice President、联盟和业务开发人员。Crew先生还是雷迪博士实验室有限公司（Dr.Reddy’；s Laboratories Ltd.）北美Vice President的一名高管。Crew先生在百时美施贵宝（Bristol-Myers Squibb）开始了他的制药职业生涯，他在该公司担任过多个全球营销、管理梦百合、营销、业务发展和战略规划方面的高级管理职位。在担任制药职务之前，Crew先生曾在美国陆军（United States Army）服役，在那里他晋升为上尉。Crew先生在波莫纳学院（Pomona College）获得经济学文学学士学位，并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
- Timothy C. Crew was appointed as the Company's Chief Executive Officer and a Director of the Company in January 2018. Mr. Crew has more than 30 years of experience in the generic and branded pharmaceutical industries. Previously, he served as Chief Executive Officer of Cipla North America, a global pharmaceutical company based in Mumbai, India. Before Cipla, he worked for eight years at Teva Pharmaceuticals Industries Ltd. "Teva", where he ultimately served as Senior Vice President and Commercial Operating Officer of the North American Generics division, the world's largest generic operation with multibillion dollars of annual sales. Before that, he was Teva's Vice President, Alliances and Business Development. Mr. Crew was also an Executive Vice President, North America, for Dr. Reddy's Laboratories Ltd. Mr. Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development and strategic planning. Prior to his pharmaceutical roles, Mr. Crew served in the United States Army, where he rose to the rank of Captain. Mr. Crew earned a Bachelor of Arts degree in economics from Pomona College and a Masters of Business Administration degree from Columbia Business School.
- Maureen M. Cavanaugh
MaureenM.Cavanaugh于2018年5月加入公司，担任高级副总裁兼首席商业运营官。在加入Teva之前，Cavanaugh女士在Teva工作了11年，最近担任高级副总裁，北美仿制药首席商务官。在Teva之前，Cavanaugh女士曾担任美国仿制药公司的高级副总裁和总经理，在此之前，她曾在销售、市场营销和客户运营方面担任多个职位。Cavanaugh女士此前还曾担任Par Pharmaceuticals的高级营销总监，Sandoz Inc.的产品管理和营销研究总监，并在百时美施贵宝公司担任过多个财务、销售与市场营销运营职位。Cavanaugh女士在拉萨尔大学（LaSalle University）获得工商管理理学学士学位，在莱德大学（Rider University）获得工商管理硕士学位。
Maureen M. Cavanaugh joined the Company in May 2018 as Senior Vice President and Chief Commercial Operations Officer. Prior to joining the Company, Ms. Cavanaugh spent 11 years at Teva, most recently as Senior Vice President, Chief Commercial Officer, North American Generics. Earlier at Teva, Ms. Cavanaugh served as Senior Vice President and General Manager, U.S. Generics and before that held a variety of positions in sales, marketing and customer operations. Ms. Cavanaugh also previously served as Senior Director of Marketing at PAR Pharmaceuticals, as Director, Product Management and Marketing Research at Sandoz Inc., and held a number of finance, sales and marketing operations positions at Bristol Myers-Squibb. Ms. Cavanaugh earned a Bachelor of Science in Business Administration degree from LaSalle University and a Masters of Business Administration degree from Rider University.- MaureenM.Cavanaugh于2018年5月加入公司，担任高级副总裁兼首席商业运营官。在加入Teva之前，Cavanaugh女士在Teva工作了11年，最近担任高级副总裁，北美仿制药首席商务官。在Teva之前，Cavanaugh女士曾担任美国仿制药公司的高级副总裁和总经理，在此之前，她曾在销售、市场营销和客户运营方面担任多个职位。Cavanaugh女士此前还曾担任Par Pharmaceuticals的高级营销总监，Sandoz Inc.的产品管理和营销研究总监，并在百时美施贵宝公司担任过多个财务、销售与市场营销运营职位。Cavanaugh女士在拉萨尔大学（LaSalle University）获得工商管理理学学士学位，在莱德大学（Rider University）获得工商管理硕士学位。
- Maureen M. Cavanaugh joined the Company in May 2018 as Senior Vice President and Chief Commercial Operations Officer. Prior to joining the Company, Ms. Cavanaugh spent 11 years at Teva, most recently as Senior Vice President, Chief Commercial Officer, North American Generics. Earlier at Teva, Ms. Cavanaugh served as Senior Vice President and General Manager, U.S. Generics and before that held a variety of positions in sales, marketing and customer operations. Ms. Cavanaugh also previously served as Senior Director of Marketing at PAR Pharmaceuticals, as Director, Product Management and Marketing Research at Sandoz Inc., and held a number of finance, sales and marketing operations positions at Bristol Myers-Squibb. Ms. Cavanaugh earned a Bachelor of Science in Business Administration degree from LaSalle University and a Masters of Business Administration degree from Rider University.